Yamauchi et al.21 have also screened and identified leukemia-specific dependence on a pre-mRNA metabolic pathway regulated by DCPS and have validated that a DCPS inhibitor, RG3039, has selective toxicity against AML but not normal blood cells. This evidence concerns the gene DCPS and acute myeloid leukemia.